Abstract:Introduction:Immunotherapies have shown promise in treating MM, although this has been limited to relapsed and refractory MM.However, their application is limited by short remission, potential toxicity, and genomic heterogeneity.Here, we used genomic subgroups and high-risk markers to identify additional potential therapeutic targets with low predicted toxicity and high specificity to MM and genomic subgroups.Methods: RNA-seq data from 754 newly diagnosed MM (NDMM) and 98 relapsed and refractory MM (RRMM) samples with genomic annotation from the CoMMpass study were utilized.32 NDMM and 43 RRMM in-house samples were used as validation.Genes with high surface potential were prioritized by annotations from 5 databases and annotation from the Human Protein Atlas was used to evaluate off-target toxicity.Candidates were further filtered to have high surface potential (>3 databases), low toxicity (normalized TPM>50 in 3).Candidates were identified at both the population and cytogenetic subgroup levels.Results: We identified 847 genes with high cell surface potential, of which 599 had low predicted off-target toxicity.48 genes with high expression were identified as candidates in both the NDMM and RRMM population, all of which were validated with consistently high expression in the validation set.They included established targets such as SLAMF7/CD319, TNFRSF17/BCMA, GPRC5D, CD38, and FCRL5/FcRH5 as well as novel targets such as EVI2B, CD53, CD79A, CD79B, and CD48.High expression of CD53 and CD48 was also associated with poor progression-free survival with quartile analysis (p=0.03, p=0.01, logrank test).By splitting the population into cytogenetic subgroups 25 more candidates were identified, including significantly upregulated ROBO3 in t(4;14), SPN in t(14;16),t(14;20) and t(4;14) and MS4A1/ CD20 in t(11;14) and t(14;16).SPN expression was significantly associated with overall survival in the three subgroups (p=0.0005,logrank test).11 unique candidates were identified for other highrisk subgroups including 1q amp, biallelic TP53, and t(MYC).Some candidates were also associated with high-risk subgroups such as GPRC5D, IL6R and SPN which showed significantly elevated expression with increasing copies of 1q (p< 0.001, p< 0.001, p< 0.04, respectively).Using the DepMap database, IL6R was essential in the 1q-gained cell-line OCI-MY7 indicating that immune escape from this target may be difficult in some patients.Conclusions: Our studies demonstrated the existence of novel increased expression of genes encoding surface proteins in NDMM patient samples that maintained their expression levels or increased when being exposed to existing standard of care in MM.In some instances, these genes associate with existing cytogenetic subgroups and may serve as novel proteins that can be further targeted by immune-related therapies.

Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival

Integrative analysis identifies CXCL11 as an immune-related prognostic biomarker correlated with cell proliferation and immune infiltration in multiple myeloma microenvironment

Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis

Genetic and Epigenetic Biomarkers with Clinical Potential

OA-33 Aberrant B Cell Differentiation Induce Plasma Cell Malignancy

Immune Escape Correlates With An Inflamed Phenotype In Malignant Mesothelioma.

Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population

Biomarkers to predict the benefits of immune‐checkpoint blockade‐based therapy in patients with malignant peritoneal mesothelioma (Review)

Cellular Interaction Analysis Characterizing Immunosuppressive Microenvironment Functions in MM Tumorigenesis from Precursor Stages

Integrative Analysis of the Prognostic Value and Immune Microenvironment of Mitophagy-Related Signature for Multiple Myeloma.

Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination

Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma

The Combination of Tumor Mutational Burden and T‐cell Receptor Repertoire Predicts the Response to Immunotherapy in Patients with Advanced Non–small Cell Lung Cancer

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for Mrna Vaccine Development.

Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring

Mesothelin Expression is Associated with Poor Outcomes in Breast Cancer

Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy

[Prognosis and immune biomarkers of multiple myeloma]

Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling

Identification of a metabolism-linked genomic signature for prognosis and immunotherapeutic efficiency in metastatic skin cutaneous melanoma